ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P16-21 Genetic/Molecular Lab Test Coding Reimbursement Policy for MHCP
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2021
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1731 - 1740 လၢ 4229 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2021 April Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P17-21 eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P15-21 New Medical, Medical Drug and Behavioral Health Policy Management Updates — Effective May 31, 2021
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 01, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP22-21 Commercial and MHCP Pharmacy Benefit Exclusion for Nulibry™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 24, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP23-21 Cellular and Gene Therapy Product Reimbursement Policy Update
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါမာ်ရှး 24, 2021
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
BCBSMN-Pharmacy-Prog-Policy-Notif_050121.pdf